Document:

Employment Agreement

 EXHIBIT 10.35 
 EMPLOYMENT AGREEMENT 
 This Employment Agreement (this
“Agreement”) is made as of the 18th day of February, 2010, by and between ImmunoCellular Therapeutics, Ltd., a Delaware corporation (the “Corporation”), and Dr. Manish Singh (hereinafter called “Executive”).

 W I T N E S S E T H: 
 WHEREAS, the Corporation previously employed Executive as its President and Chief Executive Officer under an Employment Agreement dated as of February 18, 2009 (he “Prior Agreement”);

 WHEREAS, the Corporation and Executive desire to amend certain provisions of the Prior Agreement; and 
 WHEREAS, the Corporation desires to continue to employ Executive as its President and Chief Executive Officer under a new employment
pursuant to the terms of this Agreement, and Executive is willing to accept such employment on the terms and subject to the conditions hereinafter set forth; 
 NOW, THEREFORE, in consideration of the mutual covenants hereinafter set forth, the parties hereto agree as follows: 
 1. Employment by Corporation. The Corporation hereby agrees to employ Executive to continue to perform the duties on behalf of the Corporation as the Corporation’s full-time President and
Chief Executive Officer of the Corporation. As President and Chief Executive Officer, Executive will report to the Corporation’s Chairman of the Board, and shall have such duties consistent with that of a President and Chief Executive Officer
that may from time to time be designated or assigned to Executive pursuant to the directives of the Corporation’s Board of Directors (the “Board”), including without limitation the overseeing and implementation of the
Corporation’s business plan as adopted by the Board. Executive will perform his duties under this Agreement at the Corporation’s corporate headquarters in the metropolitan Los Angeles area, with such office currently located in the
Woodland Hills, California area, or at such other location as shall be mutually agreed upon by the Corporation and Executive; and he will do such traveling as may be required of him in the performance of his duties as the President and Chief
Executive Officer. The Corporation will use its commercially reasonable efforts to have Executive serve as a member of the Board during the term of this Agreement. 
 2. Executive’s Acceptance of Employment. Executive hereby accepts such employment and agrees that throughout the period of his employment hereunder he will devote his full time, attention,
knowledge and skills, faithfully, diligently and to the best of his ability, in furtherance of the business of the Corporation, and he will perform the duties assigned to him pursuant to Section 1 hereof, subject, at all times, to the direction
and control of the Board. 

 Executive shall at all times be subject to, observe and carry out such reasonable rules,
regulations, policies, directions and restrictions as the Corporation shall from time to time establish. During the period of his employment by the Corporation, Executive agrees to be bound by the Corporation’s Code of Ethics and any amendments
adopted thereto, copies of which Executive hereby acknowledges he has received and read, and Executive agrees that he shall not, without the prior written approval of the Board, directly or indirectly, accept employment or compensation from or
perform services of any nature for, any business enterprise other than the Corporation, other than as explicitly set forth herein. 
 3. Amendment to Prior Agreement. In consideration of Executive’s agreeing to enter into this Agreement, the Corporation and Executive agree that the Prior Agreement is hereby amended to provide that the milestones set forth in
clauses (i), (ii) and (iii) of Section 4.2 of the Prior Agreement and clause (iii)(b) of Section 4.3 of the Prior Agreement may be satisfied by including the net proceeds received by the Corporation at any time prior to
August 17, 2010 from (i) the Socius Capital Group financing or (ii) from any private placement financing that is covered by a signed term sheet that was entered into by the Corporation prior to February 18, 2010, or from another
source at the same or better terms as contemplated in the signed term sheet. Any financing described in the preceding sentence shall be undertaken and the terms of such financing shall be at the discretion of the Board. For purposes of determining
whether the $8,000,000 working capital requirement of the milestone set forth in clause (iii)(b) of Section 4.3 of the Prior Agreement has been satisfied, such working capital amount shall be calculated as of the date of the
Corporation’s receipt of the proceeds that are being included to satisfy this milestone. Except as specifically set forth above, the February 17, 2010 deadline for achieving the milestones set forth in Section 4.2 and 4.3 of the Prior
Agreement is not being modified or extended. The parties further acknowledge and agree that to the extent that any portion of the option granted to Executive under the Prior Agreement is determined to have not been granted under the
Corporation’s 2006 Equity Incentive Plan (the “Plan”), the portion of the option not granted under the Plan shall be allocated to the portion of the option that is to vest under Section 4.3(iii)(b) of the Prior Agreement and
shall upon vesting remain outstanding and have all of the other terms and conditions as the portion of the option granted under the Plan. 
 4. Term. Executive shall be employed under this Agreement for a term of one year commencing on February 18, 2010 (the “Commencement Date”), and ending on February 17, 2011
unless his employment is terminated prior thereto pursuant to the provisions hereof. The term of this Agreement may be extended for an additional year, if both the Corporation and Executive deliver a written extension notice to each other no later
than the 60th calendar day prior to the expiration of the term of this Agreement. This Agreement shall automatically expire on February 17, 2011 and shall not be extended or renewed except in a writing signed by an authorized officer of the
Corporation following approval by the Board. Executive hereby acknowledges and agrees that, except in the case of the Corporation and Executive agreeing in writing to extend the term of the Agreement beyond the expiration date of this Agreement, his
employment by the Corporation, if any, beyond the expiration date of this Agreement shall be terminable by either party at will and shall not, under any circumstances, be deemed to expressly or impliedly renew the terms of this Agreement.

  

 2 

 5. Compensation/Benefits. 
 5.1 The Corporation will pay to Executive as compensation for his services hereunder an initial base salary of $300,000 per annum, payable in
equal biweekly installments. Provided that Executive continues to serve as the Corporation’s President and Chief Executive Officer for the entire one-year term of this Agreement, the Corporation shall pay Executive a discretionary cash bonus of
up to $50,000 upon completion of the one-year term. The Board of Directors of the Corporation shall annually review Executive’s performance and base salary to determine whether an increase in the amount thereof is warranted. Executive
acknowledges that he has been paid by the Corporation all amounts owing under the Prior Agreement through the date hereof. 
 5.2 The Corporation shall grant the Executive on the date of the next Board meeting under the Corporation’s 2006 Equity Incentive Plan or a new qualified stock option plan of the Corporation (collectively, the “Plan”), a
stock option (the “Option”) to purchase 600,000 shares of the Corporation’s common stock (“Common Stock”) having an exercise price per share equal to the closing market price on the date of grant and having a term of seven
years from the date of grant. The Option shall be an incentive stock option to the maximum extent that is legally permitted. This option grant shall be subject to approval by the Company’s shareholders of an increase in the authorized number of
shares under the Plan and an increase in the number of shares that can be granted to any individual under the Plan during any twelve-month period. The option shall vest (i) as to 360,000 shares in twelve equal monthly installments of
30,000 shares each over the twelve month period from and immediately following the grant date; (ii) as to 30,000 shares if the Corporation achieves during term of this Agreement a volume weighted average trading price for the Common Stock of
greater than $1.60 for any 15 consecutive trading day period during the term of this Agreement on average daily trading volume of at least 20,000 shares; (iii) as to 90,000 shares if the Corporation achieves during term of this Agreement a
volume weighted average trading price for the Common Stock of greater than $2.00 for any 15 consecutive trading day period during the term of this Agreement on average daily trading volume of at least 20,000 shares, (iv) as to 30,000 shares for
treating the first patient in a phase II clinical trial and (v) as to 90,000 shares if during the term of this Agreement the Corporation completes a financing, a strategic alliance or licensing agreement with upfront licensing payments to the
Corporation or a merger or acquisition (each of these a “Liquidity Event”) that generates at least $5,000,000 of net proceeds (after commissions) for the Corporation beyond the $10,000,000 achieved by August 17, 2010 (the merger or
acquisition proceeds for purposes of this Section 5.2 to be calculated based on the value of the net proceeds (after commissions) received or paid by the Corporation). Any Liquidity Event shall be undertaken and the terms of any Liquidity Event
shall be at the discretion of the Board. Any financing proceeds received by the Corporation during the first six months of the term of this Agreement that are used to satisfy the milestones under the Prior Agreement as described in Section 3
hereof shall not be included as proceeds to satisfy the milestones set forth in this Section 5.2 hereof. 
 The Option will
be exercisable within the seven year term of the option during the period that Executive provides services to the Corporation and for 24 months after termination for any reason except termination for cause by the Corporation, provided that such
exercise is effected within the seven-year term of the option. In the event of a Corporate Transaction (as

  

 3 

 
such term is defined in the Plan), vesting of the Option (and any other options granted to Executive) shall be governed by the provisions contained in the Corporation’s standard stock option
agreement under the Plan for the Corporation’s officers and directors, except that the portion of the Option that is to vest in monthly installments will fully vest if the Corporation is not the surviving entity in the Corporate Transaction.
The Option will have such other terms and conditions as are included in the Corporation’s standard stock option agreement under the Plan. If the term of this Agreement is extended beyond February 17, 2011, or if Executive’s employment
hereunder continues at-will beyond February 17, 2011, the Board of Directors of the Corporation shall review the aggregate number of stock options granted to the Executive promptly following such date (and thereafter not less frequently than
annually) in order to determine whether an increase in the number thereof is warranted. Any such option shall have substantially the same terms and conditions as the Option contemplated hereunder. Within 30 days following the grant of the Option to
Executive, the Corporation shall file with the U.S. Securities and Exchange Commission a registration statement on Form S-8 covering the shares of the Corporation’s common stock issuable pursuant to any options issued to Executive and
then-outstanding, to the extent the shares so issuable are not covered by an existing Form S-8 registration statement. 
 In the
event some or all of the shares covered by the Option must be cancelled as a result of the Corporation’s shareholders failing to approve the necessary amendments to the Plan to permit the grant of the Option in full, the Corporation shall be
required to grant to Executive options outside of the Plan or issue Executive restricted common stock of the Corporation having a Black-Scholes value (and such vesting and other terms and conditions as set forth in the Option) equal to the
Black-Scholes value of the shares on the date of the option grant covered by the Option that are required to be cancelled. 
 6.
Business Expenses. The Corporation will promptly reimburse Executive for all business expenses incurred by Executive in connection with the business of the Corporation in accordance with the Corporation’s policy regarding the nature and
amount of expenses and the maintenance and submission of receipts and records necessary for the Corporation to document them as proper business expenses. 
 7. Vacation. In addition to holidays observed by the Corporation, Executive shall be entitled to paid vacation of three weeks per year or such greater amount of vacation as is approved by the
Chairman of the Board. Any such vacations are to be taken at times mutually agreeable to Executive and the Chairman of the Board. Executive shall not be entitled to accrue more than six weeks of accrued vacation time at any given time. In the event
that Executive has accrued the maximum of six weeks accrued and unused vacation time, Executive shall cease accruing further vacation time until such time as Executive’s accrued and unused vacation time is less than such maximum amount.

 8. Benefits. Executive shall be entitled to all rights and benefits for which he shall be eligible under any benefit
or other plans (including, without limitation, dental, medical, medical reimbursement and hospital plans, pension plans, employee stock purchase plans, profit sharing plans, bonus plans and other so-called “fringe” benefits) as the
Corporation shall make available to its executive officers from time to time. 
  

 4 

 Executive will be offered participation in a 401K plan and the Corporation will make a
minimum match of base salary to meet the safe harbor provisions of the Internal Revenue Service (but not to exceed 3-4% of base salary). 
 9. Termination. 
 9.1 In addition to all other rights and remedies which the
parties may have under applicable law, the Corporation may terminate this Agreement and the services of Executive, effective upon the occurrence of any of the following events, any of which shall constitute a termination for “cause” under
this Agreement: (i) a failure by Executive to perform any of his material obligations under this Agreement; (ii) the death of Executive or his disability resulting in his inability to perform his reasonable duties assigned hereunder for a
period of three consecutive months; (iii) Executive’s theft, dishonesty, or falsification of any Corporation documents or records; (iv) Executive’s improper use or disclosure of the Corporation’s confidential or proprietary
information; or (v) Executive’s conviction (including any plea of guilty or nolo contendere) of any criminal act which impairs Executive’s ability to perform his or her duties hereunder or which in the Board’s judgment may
materially damage the business or reputation of the Corporation; provided, however, that prior to termination for cause arising under clause (i), Executive shall have a period of ten days after written notice from Corporation to cure the event or
grounds constituting such cause. Any notice of termination provided by Corporation to Executive under this Section 9 shall identify the events or conduct constituting the grounds for termination with sufficient specificity so as to enable
Executive to take steps to cure the same if such default is a failure by Executive to perform any of his material obligations under this Agreement. In the event Corporation terminates Executive for cause, (i) Executive shall be entitled as of
the termination date to no further base salary other than such portion of Executive’s base salary as shall have accrued but remain unpaid as of the termination date, which shall be due immediately upon termination, (ii) Executive shall be
entitled to receive payment of any earned but unpaid bonus, as well as any expense reimbursement amounts owed by the Corporation to the Executive through the date of termination and (iii) any then unexercised but outstanding stock options
granted to Executive shall be cancelled. The Corporation shall have no further obligations to Executive under this Agreement. 
 9.2 The Corporation may terminate Executive without cause upon 60 days written notice delivered to Executive. In the event the Corporation terminates Executive’s employment without cause (including a failure by the Corporation upon the
expiration of the original term of this Agreement to extend the term of Executive’s employment for an additional one year beginning February 18, 2011), all of the following will apply: (i) immediately upon termination, the Corporation
will pay to Executive any base salary as shall have accrued but remain unpaid as of the termination date, any earned but unpaid bonus and any expense reimbursement amounts owed by the Corporation to the Executive through the date of termination;
(ii) immediately upon termination, the Corporation will pay to Executive severance compensation in a lump sum cash payment equal to Executive’s then effective base salary for a period of six (6) months; (iii) any stock options
granted to Executive, to the extent vested, will be retained by the Executive and will be exercisable as detailed in Section 5.3 hereof, the Plan and related stock option agreement (which shall reflect the terms set forth in Section 5.3
hereof); and (iv) the vesting of an

  

 5 

 
additional number of shares subject to all options granted to Executive equal to 50% of all such shares subject to such options that have not already vested shall immediately accelerate and
become fully vested and exercisable by Executive and will continue to be exercisable as provided in Section 5.3 hereof, the Plan and related stock option agreement (which shall reflect the terms set forth in Section 5.3 hereof).

 9.3 Executive may terminate Executive’s employment at will (without “Good Reason” as defined below) by giving
60 days’ prior written notice to Corporation. Executive shall be entitled to (i) all base salary up to and through the 60-day period after Executive’s notice of termination is given to Corporation, any earned but unpaid bonus and any
expense reimbursement amounts owed by the Corporation to the Executive through the date of termination and (ii) any stock options, to the extent vested, may be retained by Executive and will be exercisable as detailed in Section 5.3
hereof, the Plan and applicable stock option agreement (which shall reflect the terms set forth in Section 5.3 hereof). Executive has the right to terminate Executive’s employment for “Good Reason” due to, and within a reasonable
period of time following, the occurrence of any of the following: (i) Corporation’s requirement that Executive’s principal place of work relocate more than 50 miles from its location as of the Commencement Date without the written
consent of Executive to such relocation, (ii) a material adverse change in Executive’s duties and responsibilities; (iii) any failure by Corporation to pay, or any material reduction by Corporation of, the base salary or any failure
by Corporation to pay any incentive compensation to which Executive may be entitled pursuant to Section 5 hereof; or (iv) Corporation creates a work environment designed to constructively terminate Executive or to unlawfully harass or
retaliate against Executive In the event that Executive terminates his employment for Good Reason, all of the following will apply: (A) within five days after the termination date, Corporation will pay to Executive any base salary as shall have
accrued but remain unpaid as of the termination date, any earned but unpaid bonus and any expense reimbursement amounts owed by the Corporation to the Executive through the date of termination; (B) within five days after the termination date,
Corporation will pay to Executive severance compensation in a lump sum cash payment equal to Executive’s base salary then in effect equal to six (6) months; (C) any stock options granted to Executive, to the extent vested, will be
retained by the Executive and will be exercisable as detailed in Section 5.3 hereof, the Plan and related stock option agreement (which shall reflect the terms set forth in Section 5.3 hereof); and (D) the vesting of an additional
number of shares subject to all options granted to Executive equal to 50% of all such shares (or 100% of all such shares if the Corporation is not the surviving entity in a Corporate Transaction) subject to such options that vest monthly but have
not already vested shall immediately accelerate and become fully vested and exercisable by Executive and will continue to be exercisable as provided in Section 5.3 hereof, the Plan and related stock option agreement (which shall reflect the
terms set forth in Section 5.3 hereof). 
 10. Indemnity. Executive warrants and represents that he has full power
and authority to enter into and perform this Agreement and that his performance of this Agreement will not violate the provisions of any other agreement to which he is a party. The Corporation agrees to indemnify and hold Executive harmless from and
against any and all claims, demands, causes of action, losses, damages, liability, costs and expenses, including attorneys fees arising out of his services hereunder, other than those arising from or

  

 6 

 
attributable to or resulting from his gross negligence or willful misconduct. The Corporation will name Executive as an officer on any policy of directors and officers liability insurance it
secures throughout the term of this Agreement. 
 11. Non-Competition. In consideration of the Corporation’s
entering into this Agreement: 
 11.1 Executive agrees that during the term of this Agreement he will not directly or indirectly
own, manage, operate, join, control, participate in, perform any services for, invest in, or otherwise be connected with, in any manner, whether as an officer, director, employee, consultant, partner, investor or otherwise, any business entity which
is engaged in any business in which the Corporation is currently engaged or is engaged at the termination of this Agreement without an approval from the Board. Nothing herein contained shall be deemed to prohibit (i) Executive from maintaining
any investments in, and the holding of any securities of, any company to the extent such investments were made or such securities held by Executive prior to the Commencement Date or (ii) investing his funds in securities of a company if the
securities of such company are listed for trading on a national securities exchange or traded in the over the counter market and Executive’s holdings therein represent less than 5% of the total number of shares or principal amount of other
securities of such company outstanding. 
 11.2 Executive agrees that Executive will not, during the term hereof or prior to the
expiration of one year following the termination of the Executive’s employment for any reason, without the written consent of the Corporation, directly or indirectly, by action alone or in concert with others, solicit for employment or
engagement, or advise or recommend to any other person or entity that such person or entity solicit for employment or engagement, any person or entity employed or engaged by the Corporation. 
 12. Confidentiality Agreement. 
 12.1 As used herein, the term “Confidential Information” shall mean the any and all information of the Corporation, including, but not limited to, all data, compilations, programs, devices,
strategies, or methods concerning or related to (i) the Corporation’s finances, financial condition, results of operations, employee relations, amounts of compensation paid to officers and employees and any other data or information
relating to the internal affairs of the Corporation and its operations; (ii) the terms and conditions (including prices) of sales and offers of sales of the Corporation’s products and services; (iii) the terms, conditions and current
status of the Corporation’s agreements and relationship with any customer or supplier; (iv) the customer and supplier lists and the identities and business preferences of the Corporation’s actual and prospective customers and
suppliers or any employee or agent thereof with whom the Corporation communicates; (v) the trade secrets, manufacturing and operating techniques, price data, costs, methods, systems, plans, procedures, formulas, processes, hardware, software,
machines, inventions, designs, drawings, artwork, blueprints, specifications, tools, skills, ideas, and strategic plans possessed, developed, accumulated or acquired by the Corporation; (vi) any communications between the Corporation, its
officers, directors, shareholders, or employees, and any attorney retained by the Corporation for any purpose, or any person retained or employed by such attorney for

  

 7 

 
the purpose of assisting such attorney in his or her representation of the Corporation; (vii) any other non-public information and knowledge with respect to the Corporation’s products,
whether developed or in any stage of development by the Corporation; (viii) the abilities and specialized training or experience of others who as employees or consultants of the Corporation during the Executive’s employment have engaged in
the design or development of any such products; and (ix) any other matter or thing, whether or not recorded on any medium, (a) by which the Corporation derives actual or potential economic value from such matter or thing being not
generally known to other persons or entities who might obtain economic value from its disclosure or use, or (b) which gives the Corporation an opportunity to obtain an advantage over its competitors who do not know or use the same. 

12.2 Executive acknowledges and agrees that the Corporation is engaged in a highly competitive business and has expended, or will expend,
significant sums of money and has invested, or will invest, a substantial amount of time to develop and maintain the secrecy of the Confidential Information. The Corporation has thus obtained, or will obtain, a valuable economic asset which has
enabled, or will enable, it to develop an extensive reputation and to establish long-term business relationships with its suppliers and customers. If such Confidential Information were disclosed to another person or entity or used for the benefit of
anyone other than the Corporation, the Corporation would suffer irreparable harm, loss and damage. Accordingly, Executive acknowledges and agrees that, unless the Confidential Information was (a) in the public domain or becomes publicly known
through legitimate origins not involving an act or omission by Executive, (b) was in Executive’s possession free of any obligation of confidence at or subsequent to the time such Confidential Information was communicated to Executive;
(c) was developed by Executive prior to the date of this Agreement or after the expiration of the term of this Agreement independently of and without reference to any Confidential Information; (c) was known to Executive at the time of
disclosure; or (v) was approved for release by written authorization of the Corporation, then: 
 (i) the Confidential
Information is, and at all times hereafter shall remain, the sole property of the Corporation; 
 (ii) Executive shall use his
best efforts and the utmost diligence to guard and protect the Confidential Information from disclosure to any competitor, customer or supplier of the Corporation or any other person, firm, corporation or other entity; and 
 (iii) unless the Corporation gives Executive prior express written permission, during his employment and thereafter, Executive shall not
use for his own benefit, or divulge to any competitor or customer or any other person, firm, corporation, or other entity, any of the Confidential Information which Executive may obtain, learn about, develop or be entrusted with as a result of
Executive’s employment by the Corporation. 
 12.3 Executive also acknowledges and agrees that all documentary and tangible
Confidential Information including, without limitation, such Confidential Information as Executive has committed to memory, is supplied or made available by the Corporation to the Executive solely to assist him in performing his services under this
Agreement. Executive further agrees that after his employment with the Corporation is terminated for any reason: 
 (i)
Executive shall not remove from the property of the Corporation and shall immediately return to the Corporation, all documentary or tangible Confidential Information in his possession, custody, or control and not make or keep any copies, notes,
abstracts, summaries or other record of any type of Confidential Information; and 
  

 8 

 (ii) Executive shall immediately return to the Corporation any and all other property of
the Corporation in his possession, custody or control, including, without limitation, any and all keys, security cards, passes, credit cards and marketing literature. 
 13. Invention Disclosure. Executive agrees to disclose to the Corporation promptly and fully all ideas, inventions, discoveries, developments or improvements (“Inventions”) that may be
made, conceived, created or developed by him (whether such Inventions are developed solely by him or jointly with others) during his employment by the Corporation which either (i) in any way is connected with or related to the actual or
contemplated business, work, research or undertakings of the Corporation or (ii) results from or is suggested by any task, project or work that he may do for, in connection with, or on behalf of the Corporation. Notwithstanding the foregoing,
this Section 13 shall not apply to any Inventions that meet all of the following requirements: (a) do not relate, at the time of conception, reduction to practice, creation, derivation, development or making of such Invention to the
Corporation’s business or actual or demonstrably anticipated research, development or business; and (b) were developed entirely on Executive’s own time; and (c) were developed without use of any of the Corporation’s
equipment, supplies, facilities or trade secret information; and (d) did not result from any work Executive performed for the Corporation. Executive agrees that such Inventions shall become the sole and exclusive property of the Corporation and
Executive hereby assigns to the Corporation all of his rights to any such Inventions. With respect to Inventions, Executive shall during the period of his employment hereunder and at any time and from time to time hereafter (a) execute all
documents requested by the Corporation for vesting in the Corporation the entire right, title and interest in and to the same, (b) execute all documents requested by the Corporation for filing and prosecuting such applications for patents,
trademarks and/or copyrights as the Corporation, in its sole discretion, may desire to prosecute, and (c) give the Corporation all assistance it reasonably requires, including the giving of testimony in any suit, action or proceeding, in order
to obtain, maintain and protect the Corporation’s right therein and thereto. If any such assistance is required following the termination of Executive’s employment with the Corporation, the Corporation shall reimburse Executive for his
lost wages or salary and the reasonable expenses incurred by him in rendering such assistance. 
 14. Remedies. Executive
acknowledges and agrees that the business of the Corporation is highly competitive and that the provisions of Sections 11, 12 and 13 are reasonable and necessary for the protection of the Corporation and that any violation of such covenants would
cause immediate, immeasurable and irreparable harm, loss and damage to the Corporation not adequately compensable by a monetary award. Accordingly, the Executive agrees, without limiting any of the other remedies available to the Corporation, that

  

 9 

 
any violation of said covenants, or any one of them, may be enjoined or restrained by any court of competent jurisdiction, and that any temporary restraining order or emergency, preliminary or
final injunctions may be issued by any court of competent jurisdiction, without notice and without bond. 
 15.
Attorneys’ Fees and Costs. In any action between the parties based on this Agreement, the prevailing party shall be entitled to recovery of reasonable attorneys’ fees and out-of-pocket costs incurred by such party in the action.

 16. Entire Agreement. This Agreement constitutes the entire agreement of the parties hereto with respect to the
matters set forth herein and no amendment or modification hereof shall be valid or binding unless made in writing and signed by both parties hereto. 
 17. Notices. Any notice, required, permitted or desired to be given pursuant to any of the provisions of this Agreement shall be deemed to have been sufficiently given or served for all purposes if
delivered in person or sent by certified mail, return receipt requested, postage and fees prepaid as follows: 
 if to the
Corporation, at: 
 ImmunoCellular Therapeutics, Ltd. 
 21900 Burbank Boulevard, 3rd Floor 
 Woodland Hills, CA 91367 
 with a copy to: 
 TroyGould PC 
 1801 Century Park East, Suite 1600 
 Los Angeles, California 90067 
 Attention: Sanford J. Hillsberg 
 and, if to Executive: 
 Dr. Manish Singh 
 23526 Dolorosa Street 
 Woodland Hills, California 91367 
 Either of the parties hereto may at any time and from time to time change the
address to which notice shall be sent hereunder by notice to the other party given as provided herein. The date of the giving of any notice hereunder shall be the date delivered or if sent by mail, shall be the date of the posting of the mail.

 18. Non Assignability. Neither this Agreement nor the right to receive any payments hereunder may be assigned by
Executive. This Agreement shall be binding upon Executive and inure to the benefit of his heirs, executors and administrators and be binding upon the Corporation and inure to the benefit of its successors and assigns. 
  

 10 

 19. Choice of Law And Forum. This Agreement shall be governed, interpreted and
construed under the laws of the State of California without regard to its conflict of law principles. In the event of any dispute under this Agreement, such dispute shall be resolved by binding arbitration with JAMS/ENDISPUTE in Los Angeles,
California. The arbitrator shall be a retired judge with at least five years of experience on the bench. This provision shall not be interpreted so as to require arbitration of claims that the state and/or Federal courts of California have ruled may
not be the subjects of compelled arbitration in employment matters, nor shall it be interpreted so as to restrict any remedy, right of appeal or discovery device available to either party in a manner that violates the rulings of the state and/or
Federal courts of California with respect to employment-related arbitration. This provision shall not be interpreted so as to preclude the making of reports to governmental offices, or to preclude either party from seeking injunctive or provisional
relief in a court of appropriate jurisdiction under such circumstances as may merit such relief. 
 20. Waiver. No course
of dealing nor any delay on the part of any party in exercising any rights hereunder shall operate as a waiver of any such rights. No waiver of any default or breach of this Agreement shall be deemed a continuing waiver or a waiver of any other
breach or default. 
 21. Severability. If any provision of this Agreement, including any paragraph, sentence, clause or
part thereof, shall be deemed contrary to law or invalid or unenforceable in any respect by a court of competent jurisdiction, the remaining provisions of such paragraph, sentence, clause or part thereof shall not be affected, but shall, subject to
the discretion of such court, remain in full force and effect and any invalid and unenforceable provisions shall be deemed, without further action on the part of the parties hereto, modified, amended and limited to the extent necessary to render the
same valid and enforceable. 
 22. Section 409A. If Executive becomes eligible for payments under this Agreement on
account of his “separation from service,” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended, (the “Code”) and Executive is a “specified employee” within the meaning of
Section 409A of the Code, as determined by Corporation, any portion of the payments that either do not qualify under the “short-term deferral rule” or exceed two times the lesser of (A) Executive’s “annualized
compensation” for the calendar year preceding Executive’s separation from service (in each case, as those terms are defined under Section 409A of the Code), or (B) the maximum amount that may be taken into account under
Section 401(a)(17) of the Code for the year in which Executive’s separation from service occurs, and which are not otherwise exempt from Section 409A of the Code, shall be accrued, without interest, and its payment delayed until the
first day of the seventh month following Executive’s separation from service, or if earlier, Executive’s death, at which point the accrued amount will be paid in a single, lump sum cash payment. Furthermore, Corporation shall not be
required to make, and Executive shall not be required to receive, any severance or other payment or benefit under this Agreement at such time as the making of such payment or the provision of such benefit or the receipt thereof shall result in a tax
to Executive arising under Section 409A of the Code. The preceding provisions, however, shall not be construed as a guarantee by the Corporation of any particular tax effect to Executive under this Agreement. The parties agree that for purposes
of Section 409A of the Code, the severance amounts payable under this Agreement shall be treated as a right to a series of

  

 11 

 
separate payments. This Agreement is intended to comply with, or otherwise be exempt from, Section 409A of the Code. This Agreement shall be administered, interpreted and construed in a
manner consistent with Section 409A of the Code. The Corporation and Executive agree that they will execute any and all amendments to this Agreement as they mutually agree in good faith may be necessary to ensure compliance with the provisions
of Section 409A of the Code. 
 23. Survival at Termination. The termination of Executive’s employment
hereunder by expiration of the term of this Agreement or otherwise shall not affect his obligations to the Corporation hereunder which by the nature thereof are intended to survive any such termination including, without limitation, Executive’s
obligations under Sections 11, 12, 13, 14 and 22 hereof. 
 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be duly executed as of the date first above set forth. 
  

									
	IMMUNOCELLULAR THERAPEUTICS, LTD.	 		 		 	EXECUTIVE:
					
	By:	 	 /s/ C. Kirk Peacock
	 		 		 	 /s/ Manish Singh

		 	C. Kirk Peacock	 		 		 	Dr. Manish Singh
	Its:	 	Chief Financial Officer	 		 		 	

  

 12Agreement between Dr. John Yu and ImmunoCellular

 EXHIBIT 10.36 
 AGREEMENT 
 This agreement (this
“Agreement”) effective as of March 1, 2010 (the “Effective Date”) by and between ImmunoCellular Therapeutics, Ltd., a Delaware corporation (“Company”), and Dr. John Yu, an individual (“Dr.
Yu”). 
 WHEREAS, Dr. Yu has been serving as the Company’s Chief Scientific Officer; and 
 WHEREAS, the Company and Dr. Yu desire to enter into an agreement under which Dr. Yu shall continue to serve as the Company’s
Chief Scientific Officer on the terms set forth in this Agreement, with the term of this Agreement to commence on the Effective Date. 
 NOW, THEREFORE, upon the above premises, and in consideration of the mutual covenants and agreements hereinafter contained, the Company and Dr. Yu hereto agree as follows. 
 1. Engagement. Effective as of the Effective Date, the Company shall employ Dr. Yu, and Dr. Yu shall serve, as the
Company’s Chief Scientific Officer. The Company acknowledges that Dr. Yu is a full-time employee of Cedars-Sinai Medical Center (“CSMC”) and that Dr. Yu has pre-existing obligations to CSMC and will continue to be subject to
the policies and procedures of CSMC. Pursuant to the Full Time Faculty Consulting Guidelines of CSMC, Dr. Yu has received the consent of CSMC to participate in the activities of the Company. A copy of the Consent Memorandum has been provided to
the Company. Company and Dr. Yu agree that each will comply with the Consent Memorandum and, in the event of a conflict between this Agreement and the Consent Memorandum, the terms and conditions of the Consent Memorandum shall control.

 2. Services. Dr. Yu agrees to provide to the Company services in the capacity of the Company’s Chief
Scientific Officer (the “Services”). Dr. Yu will report directly and be responsible to the Company’s Board of Directors (the “Board”). The Services will be those customarily performed by a Chief Scientific Officer for a
company such as the Company; provided, however that Dr. Yu shall provide the Services on a part-time basis. Dr. Yu will perform the Services primarily at the Company’s principal executive offices, which shall be in the Los Angeles,
California area. Dr. Yu shall perform all duties assigned to him by the Company faithfully, diligently and to the best of his ability. Such duties will include, but are not limited to, directing technology development and evaluation research,
giving public presentations on behalf of the Company, and meeting with investors and potential alliance partners. 
 3.
Term. The term for which the Services shall be performed shall commence on the Effective Date and shall terminate one year thereafter, unless sooner terminated by Dr. Yu or the Company as set forth in Section 11. 

 4. Compensation. As the total consideration for Dr. Yu’s services rendered
under this Agreement, the Company shall pay or provide Dr. Yu the following compensation and benefits: 
 4.1
Salary. Commencing on the Effective Date, Dr. Yu shall be entitled to receive an annual salary of $70,000, which shall be payable in equal bi-weekly payments. 
 4.2 Stock Options. At the first regularly scheduled meeting of the Board following the Effective Date, the Company shall grant to Dr. Yu a seven-year option to purchase 125,000 shares of the
Company’s common stock (“Option”) under the Company’s 2006 Equity Incentive Plan (the “Plan”) with an exercise price equal to the closing market price on the date of grant. The Option shall vest as to
75,000 shares in four equal quarterly installments following the date of grant and the remaining 50,000 shares shall vest pursuant to the performance milestones described in Section 4.3. The Option grant is subject to approval by the
Company’s shareholders of an increase in the authorized number of shares under the Plan. 
 4.3 Bonus. Dr. Yu
shall receive the following bonus payments and vesting of shares under the Option if the following milestones are met: 
 (a)
$15,000 and the vesting of 25,000 shares under the Option if FDA acceptance of a Phase II clinical trial plan for ICT-107 is completed by December 31, 2010; and 
 (b) $15,000 and the vesting of 25,000 shares under the Option if a PI sponsored IND submission for one of the Company’s product
candidates (ICT-107, ICT-207 or ICT-121) has been accepted by the FDA by no later than December 31, 2010. 
 The Company
will have no obligation to pay Dr. Yu any of the cash compensation or vest any of the shares covered by the Option specified in this Section 4.3 with respect to a development milestone that is not timely achieved for any reason, including
a decision by the Company in its sole discretion to delay or abandon the development of ICT-107 or any of its other product candidates for any reason. 
 5. Expenses. The Company shall reimburse Dr. Yu for necessary and reasonable out-of-pocket business expenses incurred by Dr. Yu in the performance of this Agreement in accordance with the
reimbursement policies of the Company in effect from time to time. 
 6. No Benefits. Dr. Yu acknowledges and agrees
that he will not be eligible for any Company employee benefits and, to the extent he otherwise would be eligible for any Company employee benefits but for the express terms of this Agreement, Dr. Yu hereby expressly declines to participate in
such Company employee benefits. 
 7. Withholding; Indemnification. Dr. Yu shall have full responsibility for
applicable withholding taxes for all compensation paid to him under this Agreement. Dr. Yu agrees to indemnify, defend and hold the Company harmless from any liability for, or assessment of, any claims or penalties with respect to such
withholding taxes, labor or employment requirements, including any liability for, or assessment of, withholding taxes imposed on the Company by the relevant taxing authorities with respect to any compensation paid to Dr. Yu. 
 8. Proprietary Rights. All inventions, improvements, discoveries, copyrightable or patentable works, intellectual property, whether
or not patentable or copyrightable, and all other work performed and all materials developed or prepared by Dr. Yu, in connection with the Services provided to the Company in connection with the Company’s technology, whether

  

 - 2 - 

 
developed or prepared solely or jointly by Dr. Yu with others, are the property of the Company and, as between Dr. Yu and the Company, all rights, title and interest therein shall vest
in the Company and shall be deemed to be works made for hire and made in the course of the services described above. To the extent that title to any such works may not, by operation of law, vest in the Company or such works may not be considered
works made for hire, all rights, title and interest therein are hereby irrevocably assigned to the Company. All such materials shall belong exclusively to the Company, and the Company shall have the right to obtain and to hold in its own name,
copyrights, trademarks, patents, other registrations, or such other protection as may be appropriate to the subject matter, and any extensions and renewals thereof. Dr. Yu agrees to give the Company and any person designated by the Company such
reasonable assistance, at the Company’s expense, as is required to perfect the rights defined in this Section. Dr. Yu agrees to return to the Company all materials developed or prepared for the Company by Dr. Yu upon the termination
of this Agreement, along with all materials and other property of the Company in Dr. Yu’s possession at the time of termination of this Agreement. 
 9. Confidential Information. 
 9.1 Confidentiality Obligations.
“Confidential Information” means, collectively: (a) business or technical information of the Company, including but not limited to information relating to the Company’s product plans, designs, costs, product prices and names,
finances, marketing plans, business opportunities, personnel, research, development or know-how; (b) any information designated by the Company as “confidential” or “proprietary” or which, under the circumstances taken as a
whole, would reasonably be deemed to be confidential; and (c) the terms and conditions of this Agreement. Dr. Yu hereby agrees that, except with respect to any required disclosure to CSMC (which he shall disclose in writing to the Company,
including a description of the Confidential Information required to be disclosed, before making such disclosure to CSMC, unless such disclosure relates to a patient safety issue (in which case he shall promptly advise the Company in writing after
making such safety issue disclosure to CSMC)), he (x) will not disclose to any third party or use any Confidential Information disclosed to him by the Company except as expressly permitted in this Agreement; (y) will not disclose to the
Company any Confidential Information of any third party disclosed to him by such third party without the prior written consent of such third party; and (z) will take all reasonable measures to maintain the confidentiality of all Confidential
Information of the Company in his possession or control. 
 9.2 Exclusions. “Confidential Information” will not
include information that is: (i) already lawfully known by the receiving party prior to this Agreement without restriction, (ii) in the public domain due to no fault of the receiving party, (iii) rightfully obtained by the receiving
party without similar restriction from such party, (iv) independently developed by the receiving party without reference to the other party’s confidential information, or (v) provided by the disclosing party to another party without
similar restriction. 
 10. Indemnity. Dr. Yu agrees to indemnify and hold the Company harmless from and against any
and all claims, demands, causes of action, losses, damages, liabilities, costs, and expenses, including attorneys’ fees, arising from a breach of any of his representations and warranties herein or attributable to or resulting from his gross
negligence or willful misconduct in rendering the Services. The Company agrees to indemnify and hold Dr. Yu harmless from

  

 - 3 - 

 
and against any and all claims, demands, causes of action, losses, damages, liability, costs and expenses, including attorneys fees arising out of his services hereunder, other than those arising
from Dr. Yu’s breach of any of his representations and warranties hereunder or Dr. Yu’s gross negligence or willful misconduct. 
 11. Termination of Services. The term for which the Services will be provided will terminate in advance of the times specified in Section 3 as follows: 
 11.1 Death. The term of the Services shall terminate immediately upon Dr. Yu’s death. 
 11.2 Termination by the Company. In the event that Dr. Yu shall become either physically or mentally incapacitated so as to be
incapable of performing his duties as required hereunder, and if such incapacity shall continue for a period of 45 consecutive days, the Company may, at its option, terminate the term of the Services and Dr. Yu’s duties hereunder by
written notice to Dr. Yu at that time or at any time thereafter while such incapacity continues. The Company may terminate the term of the Services for Cause (as hereinafter defined) at any time upon written notice to Dr. Yu.
“Cause” as used in this Agreement means that Dr. Yu, (i) after reasonable notice and warning, has failed to perform his assigned duties to the Company as determined by the Board of Directors, (ii) has materially breached any
of the terms or conditions of this Agreement and has failed to correct such breach within 15 days following written notice from the Company of such breach, or (iii) has been charged with a felony or any intentionally fraudulent act that
materially damages, or could reasonably be expected to materially damage, the business or reputation of the Company. 
 11.3
Termination by Dr. Yu. Dr. Yu may terminate the term of the Services at any time upon sixty (60) days written notice to the Company. 
 11.4 Payments Upon Termination. In the event of termination of this Agreement pursuant to Section 11.1, 11.2 or 11.3, Dr. Yu shall be entitled to (i) all base salary up to and
through the date of termination, (ii) any earned but unpaid bonus and any expense reimbursement amounts owed by the Company to Dr. Yu through the date of termination, and (iii) and any stock options, to the extent vested. 

12. General Terms. 
 12.1 Assignment. This Agreement is personal to Dr. Yu. He may not sell, transfer, sublicense, subcontract, hypothecate or assign his rights and duties under this Agreement without the prior
written consent of the Company. The Company may freely assign its rights and obligations under this Agreement. 
 12.2
Notices. Any notices or communications under this Agreement shall be in writing and shall be hand-delivered or sent by certified mail (return receipt requested), or telecopied, or overnight couriered to the party receiving such communication
at the address specified below: 
  

 - 4 - 

			
	If to the Company:	  	 Dr. Manish Singh, President
 ImmunoCellular Therapeutics, Ltd.
 21900 Burbank Boulevard, 3rd Floor
 Burbank, California 91367

		
	If to Dr. Yu:	  	 Dr. John Yu
 Suite 800E

 8631 West Third Street
 Los Angeles,
CA 90048

 or such other address or addressee as either party may in the future specify to the other party. 
 12.3 California Law. This Agreement shall be governed by and construed in accordance with the laws of the State of California,
excluding its conflicts of laws provisions. 
 12.4 Dispute Resolution. Any dispute arising out of or relating to this
Agreement shall be decided by binding arbitration by JAMS and shall be held in Los Angeles, California. The ruling of the arbitrator shall be final and may be enforced by any party to such arbitration in any court of competent jurisdiction located
in Los Angeles, California. 
 12.5 Amendment. No modification, amendment, supplement to or waiver of the provisions of
this Agreement shall be binding upon the parties hereto unless made in writing and duly signed by both parties. 
 12.6
Waiver. A failure of either party to exercise any right provided for herein shall not be deemed to be a waiver of any right hereunder. 
 12.7 Entire Agreement. This Agreement sets forth the entire understanding of the parties as to the subject matter therein and may not be modified except in writing executed by both parties.

 12.8 Severability. In the event any one or more of the provisions of this Agreement is invalid or otherwise
unenforceable, the enforceability of the remaining provisions shall be unimpaired. 
 12.9 Survival. The following
Sections shall survive the termination of this Agreement: 8 (Proprietary Rights), 9 (Confidentiality) and 10 (Indemnity). 
 12.10 Attorneys Fees. If an arbitration or other legal proceeding is brought to enforce or interpret the provisions of this Agreement or as to the rights or obligations of any party to this Agreement, the prevailing party in such
action shall be entitled to recover its reasonable attorneys’ fees and costs. 
 12.11 Disclosure. The terms of this
Agreement may be publicly disclosed by the Company to the extent the Company’s counsel determines that such disclosure is required by law. The Company shall provide Dr. Yu [and CSMC] with a copy of any such disclosure for his review
at least three days prior to making such disclosure. 
  

 - 5 - 

 IN WITNESS WHEREOF, the parties hereto, each acting under due and proper authority, have
executed this Agreement as of the date set forth above. 
  

							
		 		 	IMMUNOCELLULAR THERAPEUTICS, LTD.
				
	 /s/ John Yu
	 		 	By:	 	 /s/ Manish Singh

	Dr. John Yu	 		 	Name:	 	Dr. Manish Singh
		 		 	Title:	 	President and Chief Executive Officer
				
	Date:	 		 	Date:	 	

  

 - 6 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}]]